NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY
申请人:KARUS THERAPEUTICS LTD
公开号:US20150361074A1
公开(公告)日:2015-12-17
A compound of the formula: (I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.
Histone deacetylase inhibitors and their use in therapy
申请人:Karus Therapeutics Limited
公开号:US10150763B2
公开(公告)日:2018-12-11
A compound of the formula:(I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.
Vinyl functionalized alkoxy-siloxylated polyethers and polyesters
申请人:Angeletakis Christos
公开号:US20110054138A1
公开(公告)日:2011-03-03
A method is described herein for the preparation of a resin that may be used as a component in formulations of hydrosilation cured vinyl disiloxanes to increase the hydrophilicity and thereby reduce the contact angle. The resin is a vinyl functionalized alkoxy-siloxylated polyether or polyester copolymer and the method involves reacting a hydride functionalized siloxane in the presence of a Lewis acid catalyst with (a) one or more of an alcohol, a polyether diol, a polyether polyol, a polyester diol or polyester polyol and (b) a hydride functionalized siloxane containing a terminal vinyl group directly bonded to a silicon atom. This resin can be used in the formulation of dental impression materials.
US9676765B2
申请人:——
公开号:US9676765B2
公开(公告)日:2017-06-13
[EN] NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY<br/>[FR] NOUVEAUX INHIBITEURS D'HISTONE DÉACÉTYLASE ET LEUR UTILISATION EN THÉRAPIE
申请人:KARUS THERAPEUTICS LTD
公开号:WO2014072714A1
公开(公告)日:2014-05-15
A compound of the formula:(I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.